| 000 | 01797 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517073617.0 | ||
| 264 | 0 | _c20161012 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1531-8257 | ||
| 024 | 7 |
_a10.1002/mds.26429 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLim, Thien Thien | |
| 245 | 0 | 0 |
_aRasagiline for the symptomatic treatment of fatigue in Parkinson's disease. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cNov 2015 |
||
| 300 |
_a1825-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aFatigue _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndans _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKluger, Benzi M | |
| 700 | 1 | _aRodriguez, Ramon L | |
| 700 | 1 | _aMalaty, Irene A | |
| 700 | 1 | _aPalacio, Rafael | |
| 700 | 1 | _aOjo, Oluwadamilola O | |
| 700 | 1 | _aPatel, Shnehal | |
| 700 | 1 | _aGujrati, Yogesh | |
| 700 | 1 | _aNutter, Benjamin | |
| 700 | 1 | _aSwartz, Camille | |
| 700 | 1 | _aHennessy, Carol | |
| 700 | 1 | _aFernandez, Hubert H | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 30 _gno. 13 _gp. 1825-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.26429 _zAvailable from publisher's website |
| 999 |
_c25632578 _d25632578 |
||